While existing treatment options have extended survival, issues such as drug resistance and side effects persist (Giaquinto et al., 2022; Lumachi et al., 2011), creating a pressing need for the development of new anti-breast cancer drugs, particularly those targeting estrogen receptor alpha (ERα) and optimizing ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) properties (Marra et al., 2020). This evidence concerns the gene ESR1 and breast carcinoma.